4 results
The primary objective of the study is to evaluate the safety, tolerability, PK, and PD of AL002 administered in single ascending doses in healthy participants and multiple doses in participants with mild to moderate AD.
1. To determine the change in plaque characteristics of non-culprit LRPs, as measured with IVUS/NIRS, after treatment with DEB in patients with ACS.2. To develop a non-invasive algorithm that is able to detect LRPs with CT.
To determine the change in plaque characteristics after treatment with DEB of additional LRPs, as measured by IVUS / NIRS, in ACS patients.
To evaluate the efficacy of AL002 in participants with Early AD in delaying disease progression compared to standard of care